LEO Pharma’s Enstilar Foam and Taclonex Topical Suspension Receive the US FDA’s Expanded Approval for Plaque Psoriasis

LEO Pharma’s Enstilar Foam and Taclonex Topical Suspension Receive the US FDA’s Expanded Approval for Plaque Psoriasis

Shots:

  • The US FDA has granted expanded approval to the Enstilar foam, 0.005%/0.064% supported by the Enstilar Pediatric study evaluating it in adolescents with plaque psoriasis aged ≥12yrs. The FDA has extended its market exclusivity by an additional six mos. to Dec 10, 2031
  • Additionally, the FDA has approved Taclonex topical suspension for scalp and body plaque psoriasis in patients aged ≥12yrs.
  • Enstilar Foam is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid while Taclonex is a combination of betamethasone and calcipotriene in which betamethasone prevents the release of the substance causing inflammation in the body

Click here to­ read full press release/ article | Ref: BusinessWire | Image: Pharmastar